Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences Protein Patent Count Surpasses 4,000 as Firm Snatches Proteomics Lead

NEW YORK, Dec. 6 - Oxford GlycoSciences said it had achieved its goal of patenting more than 4,000 proteins and related genes, an achievement that will thrust the biotech company into the forefront of proteomics research.


"We believe that this is the largest single disease-associated protein patent portfolio," Michael Kranda, OGS's CEO, said in a statement released early Friday from the company's headquarters in the UK. "We see it [the patents] as a major corporate asset which constitutes the foundation on which we are building multiple internal drug discovery programmes."


OGS's proteomic patent portfolio includes potential targets for diseases that include cancers of the breast, liver, and pancreas, and CNS disorders like schizophrenia and dementia.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.